1. Home
  2. GSL vs VIR Comparison

GSL vs VIR Comparison

Compare GSL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

N/A

Current Price

$45.36

Market Cap

1.5B

ML Signal

N/A

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

N/A

Current Price

$11.24

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSL
VIR
Founded
2007
2016
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
GSL
VIR
Price
$45.36
$11.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
★ $51.00
$20.78
AVG Volume (30 Days)
246.0K
★ 1.6M
Earning Date
11-09-2026
11-04-2026
Dividend Yield
★ 5.66%
N/A
EPS Growth
N/A
★ 17.49
EPS
★ N/A
N/A
Revenue
N/A
★ $68,556,000.00
Revenue This Year
$2.16
$257.66
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$27.28
$4.82
52 Week High
$46.57
$11.94

Technical Indicators

Market Signals
Indicator
GSL
VIR
Relative Strength Index (RSI) 44.36 56.14
Support Level $37.00 $8.43
Resistance Level $45.07 $11.77
Average True Range (ATR) 0.93 0.51
MACD -0.28 -0.03
Stochastic Oscillator 18.37 59.73

Price Performance

Historical Comparison
GSL
VIR

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: